Immunic, Inc. announced the presentation of data from the company’s phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, in patients with celiac disease in a moderated poster session at the United European Gastroenterology Week 2023, taking place October 14-17 in Copenhagen.
